Home » About Us

The first flight of
a high-tech service company

Our history

Following several years based on the University of Auvergne campus, Aptys pharma® moved and took flight with the aim of becoming a high-tech service company with a performance-driven quality control system.

The company has continued to evolve by developing new skills, investing in a range of equipment and training, and recruiting qualified staff. Over the years, we have expanded our technological offer to include new areas of expertise and also in analytical development and drug quality control.

AptysPharma, Laboratoire Pharmaceutique, Clermont-Ferrand, France


The phases of development


Since its inception in 2002, Aptys pharma® has been able to establish partnerships with pharmaceutical and biotechnology companies by licensing its patents or developing products based on customers’ specifications.


For example, in 2003, the firm sublicensed the BiGel® technology to the Scottish biotech, Ardana Biosciences. This agreement included the royalties if marketed and funding to develop an innovative formulation, Testocream®, a new transdermal form of testosterone.


And since 2004, Aptys pharma® has signed development contracts with many pharmaceutical companies such as Johnson & Johnson, Mylan, Nordic Pharma, Biogaran, Laboratoires Théa, Galderma, Servierand biotechnological companies such as Ardana, Advicenne, Neuronax, Alizé, Auris Medical, Antev, Viramal.


In 2005, Aptys pharma® licensed the Lauriad® technology to Bioalliance Pharma for the Loramyc® / Oravig® product, now marketed by Vectans Pharma.

determined progress inectricably
linked to our ambitions


Aptys pharma® actively participates in the development of the Analgesia Partnership pain cluster, better known today as the Analgesia Institute.  And it was from within this cluster that Aptys pharma® launched the preclinical development of Metapain®, an innovative pain treatment that combines two non-opioid analgesics.


We then signed a co-development agreement with Unither Pharmaceuticals, an international CDMO, a world leader in BFS technology.


Group performance and development

The governance of Aptys pharma® is based on principles that contribute to maintaining the balance between performance and the proper development of the Group. It is ensured by a Strategy Committee, a Development Committee and an Executive Committee.

The role of the Strategy Committee is to support the management team in the development and evolution of its strategy, the analysis of its risks and opportunities, and relations with investors. The Development Committee’s is to support the management team in the development and marketing of the group’s products. The Management Committee is a forum for reflection, exchange and discussion on the challenges facing Aptys pharma® and monitors and steers the various activities.

Committee members

François Boutignon: President & CEO • doctor in Biochemistry

Following his studies at Lille and Oxford, prior to launching Aptys pharma® in 2002, François was Vice-President for R & D at Europeptides, a subsidiary of Asta Medica. He is the author of more than fifty papers and communications and the person behind ten patents.

Michel Wurm: CMO, MD

Michel began his career at Sandoz prior to other posts in the pharmaceutical industry, but always in positions of strategy management and director/VP of business development. He was also the director for strategy and business development at Pharmaleads who have notably developed a range of pain control products.

Alain Eschalier: medical Doctor • Pharmacist and professor of medical pharmacology

Alain has founded and managed research structures since 1992, and most notably the “Basic and clinical pain pharmacology” team. He was the founding director of the INSERM / UdA 1107, “Neuro-Dol” research unit and was president of the University of Auvergne. Co-founder of the Analgesia Partnership cluster, he today is president of the Analgesia Institute.

Serge Richard: Pharm.D, pharmacologist and toxicologist.

He founded ERBC, a French preclinical CRO where he is the Chairman of the Supervisory Board. He created 3P3D SAS, a start-up dedicated to the development of new molecules for the treatment of depressive disorders. He brings his experience in the field of service activity as well as in funding and management of R&D.

Eric Beyssac: Pharm D, Ph.D.

Professor of Biopharmacy at the Faculty of Pharmacy, University of Clermont Auvergne, Clermont-Ferrand – France Research Group UMR Medis. Expert in the development of specific drug dosage forms using alternative methods, such as in vitro dissolution, artificial digestive system and in vitro permeability, combined with specific formulation technologies. Development and use of in vitro in vivo correlation in drug dosage form development.

Matthias Rischer: PhD

International Expert in CMC, Matthias started his career as head of the analytical development group then head of pharmaceutical development at ASTA MEDICA AG. He was appointed managing director for the pharmaceutical development production and quality assurance at AETERNA ZENTARIS AG. He is now head of Innovation at LOSAN PHARMA and working for other drug delivery companies as scientific expert.

Thierry Legrier: master’s degree in molecular biology

Thierry started his career at Pfizer in business development positions. He then became director of medical inspection at Wyeth before joining the Grünenthal group, European leader in pain management, where he was responsible for strategy, development and sales.

Éric Morel d’Arleux: 40 years of experience in the international biomedical sector

After studying in Paris, London, and Frankfurt (European Business School), he founded and directed the French branch of Datascope, a specialist in the cardiovascular field, listed on Nasdaq. He then created Life Partners Europe, a specialist in the field of endoscopy.

Cécile Thébault : Investment director

Cécile Thebault has been working for over thirty-five years as a private equity/innovation investor, focusing mainly on life sciences and the environment (health, food, agri-food, green chemistry). Investment Director at UI Investissement, she monitors and steers the funding of several technology companies from their seed stage to their industrial transfer.

Philippe Pronnier: Docteur • anaesthetist and graduate in emergency medicine

For fifteen years, Philippe worked in France’s biggest emergency hand surgery centre at the Lille Sud clinic in Lesquin, and, as a result, has extensive experience in postoperative pain management in orthopaedics and trauma surgery.  He was then a director of a private health group for 5 years at the Métropole private Hospital.